| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.370 | Biomarker | disease | BEFREE | HER2-BBz-CAR T cells effectively clear medulloblastoma orthotopically implanted in the posterior fossa of NSG mice via both regional and intravenous delivery in xenograft models. | 29712574 | 2018 | ||||
|
0.370 | Biomarker | disease | CTD_human | Double high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for primary disseminated medulloblastoma: a report of 3 cases. | 20168248 | 2010 | ||||
|
0.370 | AlteredExpression | disease | BEFREE | Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. | 19033425 | 2009 | ||||
|
0.370 | AlteredExpression | disease | BEFREE | We identified specific microRNA expression patterns which distinguish medulloblastoma differing in histotypes (anaplastic, classic and desmoplastic), in molecular features (ErbB2 or c-Myc overexpressing tumors) and in disease-risk stratification. | 18973228 | 2009 | ||||
|
0.370 | Biomarker | disease | BEFREE | Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab? | 16724315 | 2008 | ||||
|
0.370 | Biomarker | disease | BEFREE | These data identify an ERBB2 driven prometastatic pathway that may provide a novel target for therapeutic intervention in metastatic medulloblastoma. | 12517790 | 2003 | ||||
|
0.370 | Biomarker | disease | BEFREE | Rather, we show that 17-AAG generates a dose- and time-dependent increase in MEK/ERK signaling that is required for the drug to inhibit the proliferation of medulloblastoma cells and that ERBB2 sensitizes medulloblastoma cells to 17-AAG by up-regulating basal MEK/ERK signaling. | 12709419 | 2003 | ||||
|
0.370 | AlteredExpression | disease | BEFREE | 41 primary medulloblastoma tumour samples were analysed for ErbB2 receptor expression using immunohistochemistry, and for aberrations of chromosome 17 and amplification of the MYC oncogene using fluorescence in situ hybridisation. | 11531256 | 2001 |